– Durable Responses Observed in Second Cohort of Patients in Pivotal EV-201 Trial of PADCEV and in Initial First-Line Cohort of the EV-103 Trial Evaluating PADCEV in Combination with KEYTRUDA® (pembrolizumab) –
– Data to be Presented in Virtual Scientific Program of the 2021 American Society of Clinical Oncology Annual Meeting –
San Francisco, CA (UroToday.com) — Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. announced updated results from two clinical trials examining PADCEV® (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and PADCEV in combination with Merck’s (known as MSD outside the United States and Canada) KEYTRUDA® (pembrolizumab) (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy.